{
  "outcomes_metadata": {
    "timestamp": "2025-10-04T15:08:40.636582",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "perioperative mortality",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "survival",
        "improved survival",
        "time from randomisation to death from any cause",
        "death state",
        "treatment-related deaths",
        "treatment-related mortality",
        "mortality",
        "sudden death"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "tumor response rate",
        "tumour response rate",
        "response (mRECIST)",
        "response rates (CR, PR, mRECIST)",
        "response rates (RECIST criteria)",
        "response rates (RECIST criteria for locoregional therapies)",
        "response rates (mRECIST for systemic therapy)",
        "response rates (RECIS systems for systemic therapy)",
        "response assessment (multiphase computed tomography with contrast)",
        "response assessment (magnetic resonance imaging with contrast)",
        "objective tumour response",
        "partial response (PR)",
        "partial response",
        "minor response (reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "complete remission",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "clinical benefit rate",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "tumor reduction",
        "tumour spread (TNM system)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "progression assessment (BCLC assessment system)",
        "prognosis (BCLC staging system)",
        "prognosis (Child-Pugh score)",
        "prognosis (MELD score)",
        "Barcelona Clinic Liver Cancer (BCLC) staging system",
        "BCLC staging classification",
        "Milan criteria",
        "UCSF-expanded criteria",
        "down-staging",
        "delay of recurrence",
        "recurrence",
        "disease recurrence",
        "early detection of recurrence",
        "risk of HCC development",
        "alpha-fetoprotein (AFP) monitoring",
        "alpha-fetoprotein level",
        "tumour seeding",
        "secondary cancer",
        "keratoacanthoma",
        "squamous cell cancer of the skin"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time to tumour progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "time to deterioration",
        "progression-free state",
        "progressive illness state",
        "benefit from molecular chemoembolization",
        "benefit from radioembolization (time to progression)",
        "benefit from combination of loco-regional methods (chemoembolization plus thermoablation)",
        "bridging therapy benefit (reduction of progression)",
        "local control",
        "disease progression",
        "tumour haemorrhage",
        "tumour reduction"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse reactions (general)",
        "side-effects (general)",
        "undesirable effects (general)",
        "treatment-emergent adverse events (TEAEs)",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "complication incidence",
        "complications",
        "post-treatment complications",
        "long-term treatment-related complications",
        "intraoperative complications",
        "perioperative mortality",
        "morbidity",
        "donor morbidity",
        "liver failure",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "liver disorders",
        "liver function",
        "liver function (Child-Pugh scale)",
        "bleeding",
        "haemorrhagic events",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "haemorrhage",
        "tumour haemorrhage",
        "rebleeding",
        "arterial hypertension",
        "hypertension",
        "arterial thromboembolic events",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "cardiovascular arrest",
        "cerebral vascular accident",
        "sudden death",
        "death",
        "infusion reactions",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "hand feeding reactions",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "dermatitis exfoliative",
        "dry skin",
        "erythema",
        "pruritus",
        "acne",
        "hyperkeratosis",
        "alopecia",
        "folliculitis",
        "pain",
        "abdominal pain",
        "limb pain",
        "back pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "fatigue",
        "hypodynamia",
        "hypody",
        "asthenia",
        "decreased appetite",
        "anorexia",
        "weight loss",
        "decreased weight",
        "nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro oesophageal reflux disease",
        "intestinal failure",
        "abdominal swelling",
        "nutrition",
        "body image",
        "dysgeusia",
        "taste disturbance",
        "cough",
        "dyspnoea",
        "shortness of breath",
        "respiratory failure",
        "infections",
        "sepsis",
        "influenza like illness",
        "fever",
        "jaundice",
        "lymphoedema",
        "lymphopenia",
        "neutropenia",
        "leukopenia",
        "anaemia",
        "thrombocytopenia",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "renal events",
        "renal failure",
        "proteinuria",
        "increased ALT activity",
        "increased amylase",
        "increased lipase",
        "transient increase in transaminases",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "QTc prolongation",
        "neurotoxicity",
        "peripheral sensory neuropathy",
        "tinnitus",
        "dysphonia",
        "flushing",
        "rhinorrhoea",
        "pleural effusion",
        "edema",
        "portal vein thrombosis",
        "ischaemic stroke",
        "stroke",
        "hypersensitivity to monitoring",
        "infusion reactions",
        "drug withdrawal due to adverse events",
        "adverse reactions leading to discontinuation of treatment",
        "adverse events leading to discontinuation",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity",
        "treatment-related deaths",
        "treatment-related mortality",
        "tolerance of treatment",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "sudden death",
        "death"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "discontinuation of treatment due to adverse events",
        "drug withdrawal due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "health status (EQ-5D visual analogue scale)",
        "FACT-G (Functional Assessment of Cancer Therapy â€“ General)",
        "FACT-G",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "SF-36",
        "visual analogue scale",
        "overall quality of life (measured with a validated and reliable instrument)",
        "quality of life weights",
        "health state utility values"
      ],
      "functional_status": [
        "overall condition (ECOG Performance Status)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "physical complaints",
        "psychological complaints",
        "psychosocial problems",
        "general complaints",
        "distress"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "pain",
        "fever (EORTC QLQ-HCC18)",
        "fever",
        "jaundice (EORTC QLQ-HCC18)",
        "jaundice",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "abdominal swelling",
        "fatigue (EORTC QLQ-HCC18)",
        "fatigue",
        "nutrition",
        "body image",
        "days of missed work",
        "length of hospital stay",
        "early diagnosis"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness analysis",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-benefit analysis",
        "cost per quality-adjusted life year (QALY)",
        "budget impact"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "resource utilization",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "false positives",
        "intention-to-treat analysis",
        "early diagnosis",
        "down-staging",
        "donor morbidity",
        "success rate (downstaging/bridging)",
        "bridging therapy benefit (reduction of progression)",
        "benefit from molecular chemoembolization",
        "benefit from radioembolization (time to progression)",
        "benefit from combination of loco-regional methods (chemoembolization plus thermoablation)",
        "effectiveness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "local tumour control"
      ],
      "biomarkers": [
        "blood and tumour biomarkers",
        "plasma pharmacokinetics parameters",
        "pharmacokinetic parameters",
        "alpha-fetoprotein (AFP) monitoring",
        "alpha-fetoprotein level"
      ]
    }
  }
}